Medpace (NASDAQ:MEDP) Shares Gap Down – What’s Next?

Medpace Holdings, Inc. (NASDAQ:MEDP) shares gapped down prior to trading on Tuesday . The stock had previously closed at $530.35, but opened at $489.00. Medpace shares last traded at $456.5890, with a volume of 184,772 shares changing hands.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q4 results beat consensus — EPS of $4.67 vs. $4.18 expected and revenue of $708.5M (up 32% YoY). Strong margins and ROE reinforce the quality of the quarter. Business Wire: Q4 & FY2025 Results
• Positive Sentiment: Management provided FY‑2026 guidance above prior expectations — EPS range 16.68–17.50 and revenue guide ~$2.8–2.9B, signaling continued high-single/low‑double‑digit growth visibility. (Guidance underpins upside to 2026 earnings). Business Wire: Guidance Details
• Neutral Sentiment: Earnings call color — management reiterated drivers (therapeutic mix, international growth, disciplined buybacks) but gave detail that some analysts view as mixed; read the full call transcript for nuance on bookings and timing. Seeking Alpha: Q4 2025 Call Transcript
• Negative Sentiment: Backlog and booking dynamics flagged as concern — analysts and commentaries describe backlog growth as “stale/sluggish,” which tempers confidence in sustained revenue acceleration despite a healthy book‑to‑bill. That narrative pressured the stock. Seeking Alpha: Great Quarter, Stale Backlog
• Negative Sentiment: Market reaction and headlines highlighted a “key negative” (timing/contract mix impact and perceived in‑line elements of guidance), triggering short‑term profit taking despite the beat — several outlets noted the stock dropped on the news. Investing.com: Shares Tumble Despite Beat MSN: Key Negative Explained

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. TD Cowen reaffirmed a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Mizuho set a $660.00 target price on shares of Medpace in a research report on Friday, January 9th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Finally, BMO Capital Markets began coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Medpace currently has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Stock Down 15.2%

The stock has a 50 day moving average of $578.30 and a 200 day moving average of $539.57. The company has a market capitalization of $12.67 billion, a price-to-earnings ratio of 31.53, a price-to-earnings-growth ratio of 1.82 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the business earned $3.67 EPS. The company’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at $3,542,100. This represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 302,192 shares of company stock valued at $182,019,762. 20.30% of the stock is currently owned by insiders.

Institutional Trading of Medpace

Several large investors have recently modified their holdings of MEDP. Essex Financial Services Inc. bought a new position in Medpace during the fourth quarter worth $274,000. Core Wealth Advisors LLC acquired a new position in shares of Medpace during the fourth quarter valued at about $47,000. Impact Partnership Wealth LLC bought a new position in shares of Medpace during the 4th quarter worth about $545,000. Norges Bank acquired a new stake in shares of Medpace in the 4th quarter valued at about $102,156,000. Finally, Eurizon SLJ Capital Ltd acquired a new stake in shares of Medpace in the 4th quarter valued at about $5,454,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.